Glaukos二季度收入大幅增长并上调全年销售指引，但同一财报催化已处理

ALISO VIEJO, Calif.--(BUSINESS WIRE)--
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the second quarter ended June 30, 2026. Key highlights include:
Record net sales of $185.6 million in Q2 2026 increased 50% year-over-year on a reported basis and 49% year-over-year on a constant currency basis.
Glaucoma record net sales of $155.2 million in Q2 2026 increased 50% year-over-year.
U.S. Glaucoma record net sales of $118.5 million in Q2 2026 increased 64% year-over-year.
Gross margin of approximately 82% and non-GAAP gross margin of approximately 85% in Q2 2026.
Raised 2026 net sales guidance to $680 million to $700 million, compared to $620 million to $635 million previously.
“Our record second quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in
iDose TR
and
Epioxa
,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Second Quarter 2026 Financial Results
Net sales in the second quarter of 2026 of $185.6 million increased 50% on a reported basis, or 49% on a constant currency basis, compared to $124.1 million in the same period in 2025.
Gross margin for the second quarter of 2026 was approximately 82%, compared to approximately 78% in the same period in 2025. Non-GAAP gross margin for the second quarter of 2026 was approximately 85%, compared to approximately 83% in the same period in 2025.
Selling, general and administrative (SG&A) expenses for the second quarter of 2026 increased 39% to $116.1 million, compared to $83.4 million in the same period in 2025. Non-GAAP SG&A expenses for the second quarter of 2026 increased 34% to $111.7 million, compared to $83.1 million in the same period in 2025.
GAAP and non-GAAP research and development (R&D) expenses for the second quarter of 2026 increased 40% to $51.3 million, compared to $36.5 million in the same period in 2025.
Loss from operations in the second quarter of 2026 was $17.3 million, compared to operating loss of $22.7 million in the second quarter of 2025. Non-GAAP loss from operations in the second quarter of 2026 was $7.6 million, compared to non-GAAP operating loss of $16.6 million in the second quarter of 2025.
Net loss in the second quarter of 2026 was $18.4 million, or ($0.31) per diluted share, compared to net loss of $19.7 million, or ($0.34) per diluted share, in the second quarter of 2025. Non-GAAP net loss in the second quarter of 2026 was $8.3 million, or ($0.14) per diluted share, compared to non-GAAP net loss of $13.6 million, or ($0.24) per diluted share, in the second quarter of 2025.
Included in non-GAAP loss from operations, non-GAAP net loss, and non-GAAP EPS for the second quarter of 2026 is an acquired in-process R&D (IPR&D) charge of $1.5 million, which caused the non-GAAP loss per diluted share to have an additional loss of ($0.02) in the second quarter of 2026.
The company ended the second quarter of 2026 with approximately $289.3 million in cash and cash equivalents, short-term investments and restricted cash, and no debt.
2026 Revenue Guidance
The company expects 2026 net sales to be in the range of $680 million to $700 million based on the latest foreign currency exchange rates.
Webcast & Conference Call
The company will host a conference call and simultaneous webcast today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information about the company’s financial outlook. A link to the webcast is available on the company’s website at
http://investors.glaukos.com
. To participate in the conference call, please dial 833-461-5787 (U.S.) or 585-542-9983 (international) and enter Conference ID 626961391. A replay of the webcast will be archived on the company’s website following completion of the call.
Quarterly Summary Document
The company has posted a document on its Investor Relations website under the “Financials & Filings – Quarterly Results” section titled “Quarterly Summary.” This Quarterly Summary document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company’s business objectives and strategies, and any forward statements or guidance the company may make. This document is provided alongside the company’s earnings press release and is designed to be read by investors before the regularly scheduled quarterly conference call. It is the company’s goal that this format will make its quarterly earnings process more efficient and impactful for the investment community.
About Glaukos
Glaukos (
www.glaukos.com
) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for
iDose
®
TR
, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our
iDose TR
and
Epioxa
therapies; the impact of general macroeconomic conditions including foreign currency fluctuations and future public health crises; supply and/or manufacturing disruptions, including those impacting our principal revenue-producing products, including the risk of recalls or serious safety issues with our products; our ability to achieve or sustain profitability, generate sales of our commercialized products and develop and commercialize additional products; risks associated with our international operations; our ability to meet our customers’ expectations for the quality or delivery of our pr